various beta blockers trial summary

All type of patient: 3 trials - HAPPHY - Yurenev - STOP

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	1.02 [0.83 1.25]	p=1.00	0	6569	1	HAPPHY,
Cardiovascular death	0.94 [0.65 1.36]	p=1.00	0	6569	1	HAPPHY,
myocardial infarction (fatal and non fatal)	1.13 [0.88 1.45]	p=1.00	0	6873	2	HAPPHY,Yurenev,
stroke (fatal and non fatal)	0.73 [0.48 1.12]	p=1.00	0	6873	2	HAPPHY,Yurenev,
Coronary event	no data
Heart failure	1.44 [0.84 2.49]	p=1.00	0	6569	1	HAPPHY,
Diabetes onset	no data
All cause death	0.91 [0.69 1.21]	p=1.00	0	6873	2	HAPPHY,Yurenev,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

suggested cardiovascular events by 38% (not demonstrated)

suggested Cardiovascular death by 58% (not demonstrated)

suggested Heart failure by 51% (not demonstrated)

suggested All cause death by 43% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.62 [0.44 0.87]	p=0.04	0	1627	1	STOP,
Cardiovascular death	0.42 [0.23 0.74]	p=0.04	0	1627	1	STOP,
myocardial infarction (fatal and non fatal)	0.90 [0.52 1.55]	p=1.00	0	1627	1	STOP,
stroke (fatal and non fatal)	0.55 [0.35 0.87]	p=0.04	0	1627	1	STOP,
Coronary event	no data
Heart failure	0.49 [0.28 0.85]	p=0.04	0	1627	1	STOP,
Diabetes onset	no data
All cause death	0.57 [0.38 0.87]	p=0.04	0	1627	1	STOP,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Uncomplicated hypertension: 3 trials - HAPPHY - Yurenev - STOP

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	1.02 [0.83 1.25]	p=1.00	0	6569	1	HAPPHY,
Cardiovascular death	0.94 [0.65 1.36]	p=1.00	0	6569	1	HAPPHY,
myocardial infarction (fatal and non fatal)	1.13 [0.88 1.45]	p=1.00	0	6873	2	HAPPHY,Yurenev,
stroke (fatal and non fatal)	0.73 [0.48 1.12]	p=1.00	0	6873	2	HAPPHY,Yurenev,
Coronary event	no data
Heart failure	1.44 [0.84 2.49]	p=1.00	0	6569	1	HAPPHY,
Diabetes onset	no data
All cause death	0.91 [0.69 1.21]	p=1.00	0	6873	2	HAPPHY,Yurenev,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

suggested cardiovascular events by 38% (not demonstrated)

suggested Cardiovascular death by 58% (not demonstrated)

suggested Heart failure by 51% (not demonstrated)

suggested All cause death by 43% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.62 [0.44 0.87]	p=0.04	0	1627	1	STOP,
Cardiovascular death	0.42 [0.23 0.74]	p=0.04	0	1627	1	STOP,
myocardial infarction (fatal and non fatal)	0.90 [0.52 1.55]	p=1.00	0	1627	1	STOP,
stroke (fatal and non fatal)	0.55 [0.35 0.87]	p=0.04	0	1627	1	STOP,
Coronary event	no data
Heart failure	0.49 [0.28 0.85]	p=0.04	0	1627	1	STOP,
Diabetes onset	no data
All cause death	0.57 [0.38 0.87]	p=0.04	0	1627	1	STOP,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Various beta blockers beta-blockers